Where can we make a significant impact in a disease area in which so much is being done already? At Evotec, we have had a long history of contribution to the oncology field through our partners, both industrial and not-for-profit. However, we have recently asked ourselves where we could leverage internal expertise and technology to create impacting value for patients. The result was an investment in what we consider soon to be leading therapeutic approaches for cancer.

In this fourth edition of our DDup (Drug Discovery Update), we delve into the exciting new field of epigenetics, where Evotec has embarked
on a novel collaboration model with Dana-Farber and the Belfer Institute for Applied Cancer Science to identify the next generation of epigenetic drug targets. Evotec brings to the table a wealth of drug discovery and biomarker discovery experience, providing an industrial edge to the drug hunting process. The Belfer Institute, in alliance with the DanaFarber Cancer Institute, contributes target validation workflows, in vivo models and genomic data to support identification of patient stratification biomarkers. One of the advantages of the model is that it allows us to rapidly progress novel targets from target validation stage all the way through to identification of a pre-clinical drug candidate.

Learn more about epigenetics and cancer in this Drug Discovery Update #4.